Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT

Model scores of the 29,894 trials active now.

Model score 37% for any early termination, 19% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2018-12-26. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cttumortumorsradiationreceptor positive
  Phrases that lowered it: clinical trialfixedresultspluspositive
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Drug's FAERS reports with a death: 27.7% (raises risk) · Drug's FDA history
• Sponsor's past termination rate: no earlier finished trials (lowers risk) · Sponsor's track record
• Disease area, cancer: Yes (raises risk) · Disease area
• Responsible party: sponsor investigator (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 1 (raises risk) · Sponsor's track record
• Number of arms: 1 (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Design: single group (raises risk) · Design
• Sponsor's past trials: 0 (raises risk) · Sponsor's track record
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Maximum age: not given (raises risk) · Who can join
• Collaborators: 1 (raises risk) · Design
• Primary purpose: diagnostic (lowers risk) · Design
• Drug's FAERS reports in the prior 12 months: 528 (raises risk) · Drug's FDA history
• Blinding: none (raises risk) · Design
• Drug's FAERS reports marked serious: 94.4% (raises risk) · Drug's FDA history
• Minimum age: 2 (lowers risk) · Who can join
• Drug's FAERS reports before start: 2259 (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors NCT01619865 · started 2012 · scored riskier than 96% of active trials completed
• Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors NCT02441062 · started 2015 · scored riskier than 92% of active trials completed
• 68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs) NCT02359500 · started 2014 · scored riskier than 84% of active trials terminated
• Al18F-NOTA-octreotide PET Imaging in Neuroendocrine Tumors NCT04552847 · started 2020 · scored riskier than 60% of active trials completed
• 177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms NCT01237457 · started 2010 · scored riskier than 99% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.